Amag Pharmaceuticals Inc., of Waltham, Mass., reported total revenues of $123.9 million for the second quarter, with the increase over last year primarily related to the addition of Makena (hydroxyprogesterone caproate injection), a drug approved for pre-term birth, in November 2014, which contributed $63.6 million in net product sales in the second quarter, and the recognition of $39.2 million of collaboration revenue related to the termination of the company's ex-U.S. marketing agreement for iron deficiency anemia drug Feraheme (ferumoxytol).